Vascular function in patients with end-stage renal disease and/or coronary artery disease: A cardiac magnetic resonance imaging study

Kidney International

Volumn 71, Issue 1, 2007, Pages 68-73

  Zimmerli, L U ^a   Mark, P B ^a   Steedman, T ^a,b   Foster, J E ^a,b   Berg, G A ^c   Dargie, H J ^a,b   Jardine, A G ^a   Delles, C ^a   Dominiczak, A F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Arteriosclerosis; Coronary artery disease; Dialysis; ESRD

Indexed keywords

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART FUNCTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

AGED; AORTA; BLOOD VESSELS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; VASCULAR RESISTANCE;

EID: 33845701232     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002024     Document Type: Article

References (32)

1. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Dial 1999; 12: 69-76.
2. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol 2003; 16: 476-486.
3. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439.
4. Guerin AP, Blacher J, Pannier B et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103: 987-992.
5. Bottini PB, Carr AA, Prisant LM et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995; 8: 221-228.
6. Myerson SG, Montgomery HE, World MJ, Pennell DJ. Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension 2002; 40: 673-678.
7. Metafratzi ZM, Efremidis SC, Skopelitou AS, De Roos A. The clinical significance of aortic compliance and its assessment with magnetic resonance imaging. J Cardiovasc Magn Reson 2002; 4: 481-491.
8. Rogers WJ, Hu YL, Coast D et al. Age-associated changes in regional aortic pulse wave velocity. J Am Coll Cardiol 2001; 38: 1123-1129.
9. Guerin AP, Marchais SJ, Metivier F, London GM. Arterial structural and functional alterations in uraemia. Eur J Clin Invest 2005; 35(Suppl 3): 85-88.
10. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021.
11. Ibels LS, Alfrey AC, Huffer WE et al. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790-796.
12. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
13. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942.
14. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
15. Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933.
16. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
17. Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000; 32: 579-583.
18. Thompson BH, Stanford W. Update on using coronary calcium screening by computed tomography to measure risk for coronary heart disease. Int J Cardiovasc Imaging 2005; 21: 39-53.
19. Groenink M, De Roos A, Mulder BJ et al. Biophysical properties of the normal-sized aorta in patients with Marfan syndrome: evaluation with MR flow mapping. Radiology 2001; 219: 535-540.
20. Resnick LM, Militianu D, Cunnings AJ et al. Direct magnetic resonance determination of aortic distensibility in essential hypertension: relation to age, abdominal visceral fat, and in situ intracellular free magnesium. Hypertension 1997; 30: 654-659.
21. Toikka JO, Niemi P, Ahotupa M et al. Large-artery elastic properties in young men: relationships to serum lipoproteins and oxidized low-density lipoproteins. Arterioscler Thromb Vasc Biol 1999; 19: 436-441.
22. US Renal Data System, USRDS 2005 Annual Data Report. Atlas of End-Stage Renal Disease in the United States, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2005.
23. De Lima JJ, Sabbaga E, Vieira ML et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension 2003; 42: 263-268.
24. Bellenger NG, Davies LC, Francis JM et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000; 2: 271-278.
25. Constantine G, Shan K, Flamm SD, Sivananthan MU. Role of MRI in clinical cardiology. Lancet 2004; 363: 2162-2171.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
27. Mark PB, Johnston N, Groenning BA et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006; 69: 1839-1845.
28. Asmar R, Benetos A, London G et al. Aortic distensibility in normotensive, untreated and treated hypertensive patients. Blood Press 1995; 4: 48-54.
29. Avolio AP, Chen SG, Wang RP et al. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation 1983; 68: 50-58.
30. Benetos A, Adamopoulos C, Bureau JM et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105: 1202-1207.
31. Cohn JN, Finkelstein SM. Abnormalities of vascular compliance in hypertension, aging and heart failure. J Hypertens Suppl 1992; 10: S61-S64.
32. Vaitkevicius PV, Fleg JL, Engel JH et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation 1993; 88: 1456-1462.